A new treatment approach called Mitral Valve Clipping, technically known as Transcatheter Edge-to-Edge Repair (TEER), is transforming care for patients with mitral regurgitation, according to a report published on April 1, 2026. The condition occurs when the mitral valve fails to close properly, causing blood to flow backward into the left atrium and leading to complications such as heart failure and irregular heartbeat. Traditionally, open-heart surgery was the main treatment, but many patients, especially the elderly or those with other organ complications, were not suitable candidates.

The TEER procedure, using Abbott Laboratories’ MitraClip device, allows doctors to repair the valve without opening the chest or stopping the heart. A catheter is inserted through the femoral vein to deliver a clip that joins the valve’s leaflets, reducing backward blood flow. Studies, including the COAPT Trial, have shown that this method lowers hospitalizations and mortality while improving quality of life. Based on these findings, major cardiology societies have recognized TEER as an important treatment option.

However, the method is not suitable for all patients, particularly those with severe valve calcification, enlarged ventricles, or active infections, making expert evaluation essential.